BETs abet Tam-R in ER-positive breast cancer
- PMID: 25001387
- PMCID: PMC4123300
- DOI: 10.1038/cr.2014.90
BETs abet Tam-R in ER-positive breast cancer
Abstract
Epigenetic modifications such as histone acetylation play a central role in the transcriptional regulation of many oncogenic drivers. Accumulating evidence suggests that pharmacological modulation of certain key epigenetic reader proteins such as BRD2/3/4 may serve as an attractive strategy for treatment of many cancers, including tamoxifen-resistant breast cancer.
Figures
References
-
- Early Breast Cancer Trialists' Collaborative G. Lancet. 2005;365:1687–1717.
-
- Roop RP, Ma CX. Future Oncol. 2012. pp. 273–292. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
